Tisotumab vedotin is the most recently approved ADC drug with an average DAR of 4, which contains a fully humanized mAb binding to tissue factor (TF), a cleavable mc-VC-PABC linker, and an antimitotic agent, MMAE.234 TF plays an important role in tumor growth, angiogenesis and metastasis and is specifically overexpressed on several solid tumors.235 Tisotumab vedotin aims to target TF antigen on cancer cells and deliver cytotoxic agent MMAE directly into cancer cells. This evidence concerns the gene TF and cancer.